Background It has been proposed that magnetic resonance imaging (MRI) be used to guide
breast cancer surgery by differentiating residual tumor from pathologic complete response …

Neoadjuvant (primary systemic) treatment has become a standard option for primary
operable disease for patients who are candidates for adjuvant systemic chemotherapy …

The use of breast magnetic resonance imaging (MRI) is rapidly increasing. EUSOMA
organised a workshop in Milan on 20–21st October 2008 to evaluate the evidence currently …

Objectives This systematic review aimed to assess the role of magnetic resonance imaging
(MRI) in evaluating residual disease extent and the ability to detect pathologic complete …

BACKGROUND: Increased pathologic complete response (pCR) rates observed with
neoadjuvant chemotherapy (NCT) for some subsets of patients with invasive breast cancer …

Pathologic complete remission after neoadjuvant chemotherapy has a role in guiding the
management of breast cancer. The present meta-analysis examined the accuracy of contrast …

Dynamic contrast‐enhanced MRI (DCE‐MRI) is an evolving tool for determining breast
disease, which benefits from the move to imaging at 3 T. It has major capabilities for the …

The past few decades have seen an increase in both the role and the complexity of
neoadjuvant therapy for breast cancer. Neoadjuvant therapy was initially described as …

Objective To explore the predictive value of MRI parameters and tumour characteristics
before neoadjuvant chemotherapy (NAC) and to compare changes in tumour size and …

BACKGROUND. This study investigated the role of magnetic resonance imaging (MRI) in
evaluation of pathologically complete response and residual tumors in patients who were …